The dataset ranks 78 assignees, with the top-ranked holder at 101 records out of 442 total and a steep drop to 29 records at fifth place and 17 at tenth. This pattern indicates a single dominant platform filer well ahead of a more evenly matched second tier, rather than a handful of equally sized competitors. Anyone assessing competitive position in this space should treat the leader’s portfolio as the primary freedom-to-operate check before looking at the rest of the field.

Filing activity peaked in 2019 at 92 records and has since settled into a lower, flatter pattern, with the comparable 2021-to-2024 figures both at 32 filings — a 0% change over that span. This reads as a plateau rather than a decline, especially because publication typically lags filing by around 18 months, so the 2025 and 2026 figures in any dataset will understate true recent activity. A practitioner should not conclude the technology is losing investment based on the most recent one or two years alone.

The dominant classification is C12M, covering bioreactors and enzyme apparatus, which appears on 55.4% of the 442 records in scope. A61M body-fluid device claims follow at 20.8%, with C12N microorganism and genetic engineering claims, A61K medicinal preparation claims, and separation, lab-apparatus and centrifuge classes each appearing on roughly 9-21% of records. Because a single record can carry multiple IPC classes, these shares add up to more than 100% and should not be summed into a single total.